Niederkorn J Y, Shadduck J A, Albert D, Essex M
Invest Ophthalmol Vis Sci. 1981 May;20(5):598-605.
The humoral immune response to a virally induced feline model of human uveal melanoma was studied by examining sera from cats bearing iridal and choroidal melanomas for antibody to the feline oncornavirus-associated cell membrane antigen (FOCMA). Anti-FOCMA antibodies appeared earlier and in higher titers in cats that ultimately expressed nonprogressing uveal melanomas. By 8 weeks after virus inoculation 56% of the cats with nonprogressing lesions had anti-FOCMA antibodies, whereas only 7% of the cats with progressive tumors produced demonstrable antibodies against FOCMA. Mean serum antibody titers were approximately 10 times higher in cats with nonprogressive lesions than in cats with progressive tumors. Similar trends were observed throughout the 28-week study period. Early appearance and a high titer of serum antibody against FOCMA correlated with nonprogressing uveal melanoma. The results indicated that uveal melanomas could be immunogeneic and successfully managed by the host's immune system.
通过检测患有虹膜和脉络膜黑色素瘤的猫的血清中针对猫肿瘤病毒相关细胞膜抗原（FOCMA）的抗体，研究了对病毒诱导的人类葡萄膜黑色素瘤猫模型的体液免疫反应。在最终表现为非进展性葡萄膜黑色素瘤的猫中，抗FOCMA抗体出现得更早且滴度更高。在病毒接种后8周，56%患有非进展性病变的猫产生了抗FOCMA抗体，而只有7%患有进展性肿瘤的猫产生了可检测到的抗FOCMA抗体。非进展性病变猫的平均血清抗体滴度比进展性肿瘤猫高约10倍。在整个28周的研究期间都观察到了类似的趋势。抗FOCMA血清抗体的早期出现和高滴度与非进展性葡萄膜黑色素瘤相关。结果表明，葡萄膜黑色素瘤可能具有免疫原性，并能被宿主的免疫系统成功控制。
